Shea, S.M.; Thomas, K.A.; Rassam, R.M.G.; Mihalko, E.P.; Daniel, C.; Sullenger, B.A.; Spinella, P.C.; Nimjee, S.M.
Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion. Pharmaceuticals 2022, 15, 1450.
https://doi.org/10.3390/ph15121450
AMA Style
Shea SM, Thomas KA, Rassam RMG, Mihalko EP, Daniel C, Sullenger BA, Spinella PC, Nimjee SM.
Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion. Pharmaceuticals. 2022; 15(12):1450.
https://doi.org/10.3390/ph15121450
Chicago/Turabian Style
Shea, Susan M., Kimberly A. Thomas, Rassam M. G. Rassam, Emily P. Mihalko, Christina Daniel, Bruce A. Sullenger, Philip C. Spinella, and Shahid M. Nimjee.
2022. "Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion" Pharmaceuticals 15, no. 12: 1450.
https://doi.org/10.3390/ph15121450
APA Style
Shea, S. M., Thomas, K. A., Rassam, R. M. G., Mihalko, E. P., Daniel, C., Sullenger, B. A., Spinella, P. C., & Nimjee, S. M.
(2022). Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion. Pharmaceuticals, 15(12), 1450.
https://doi.org/10.3390/ph15121450